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OBJECTIVES We sought to compare the in-hospital mortality of patients with acute decompensated heart
failure (ADHF) who were receiving parenteral treatment with one of four intravenous
vasoactive medications.
BACKGROUND There are limited data regarding the effects of the choice of intravenous vasoactive medication
on in-hospital mortality in patients hospitalized with ADHF.
METHODS This was a retrospective analysis of observational patient data from the Acute Decompensated
Heart Failure National Registry (ADHERE), a multicenter registry designed to prospectively
collect data on each episode of hospitalization for ADHF and its clinical outcomes. Data from
the first 65,180 patient episodes (October 2001 to July 2003) were included in this analysis.
Cases in which patients received nitroglycerin, nesiritide, milrinone, or dobutamine were
identified and reviewed (n  15,230). Risk factor and propensity score-adjusted odds ratios
(ORs) for in-hospital mortality were calculated.
RESULTS Patients who received intravenous nitroglycerin or nesiritide had lower in-hospital mortality
than those treated with dobutamine or milrinone. The risk factor and propensity score-
adjusted ORs for nitroglycerin were 0.69 (95% confidence interval [CI] 0.53 to 0.89, p 
0.005) and 0.46 (94% CI 0.37 to 0.57, p 0.005) compared with milrinone and dobutamine,
respectively. The corresponding values for nesiritide compared with milrinone and dobut-
amine were 0.59 (95% CI 0.48 to 0.73, p  0.005) and 0.47 (95% CI 0.39 to 0.56, p 
0.005), respectively. The adjusted OR for nesiritide compared with nitroglycerin was 0.94
(95% CI 0.77 to 1.16, p  0.58).
CONCLUSIONS Therapy with either a natriuretic peptide or vasodilator was associated with significantly lower
in-hospital mortality than positive inotropic therapy in patients hospitalized with ADHF.
The risk of in-hospital mortality was similar for nesiritide and nitroglycerin. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.051Cardiol 2005;46:57–64) © 2005 by the American College of Cardiology Foundation
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deart failure (HF) is a major and growing public health
oncern, significantly impairing quality of life and reducing
See page 65
ife expectancy for nearly five million Americans (1). It is the
eading cause of hospitalization in patients older than 65
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cios Inc.; and Dr. Fonarow is a consultant for Scios Inc. and Biosite.u
Manuscript received September 27, 2004; revised manuscript received March 3,
005, accepted March 10, 2005.ears of age and is a primary hospital discharge diagnosis in
pproximately 1 million people of all ages each year (1,2).
stimates of the direct costs associated with HF care in the
.S. range from $25 billion annually to nearly twice this
mount (1,3). The majority of costs—approximately two-
hirds—are attributable to the management of episodes of
cute HF decompensation (i.e., hospitalization) (3). The
equelae of acute decompensated heart failure (ADHF)
nclude prolonged in-hospital lengths of stay, unacceptably
igh rates of hospital readmission, and substantial rates of
npatient and outpatient morbidity and mortality (4–6).
Although there are published recommendations guiding
he evaluation and treatment of outpatients with chronic
F (7,8), no such guidelines exist for the management of
DHF. The development of such guidelines has been
elayed by the lack of an adequate evidence base. In fact,
ntil recently, little was known about the epidemiology,
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Hospital Mortality in Decompensated HF July 5, 2005:57–64atural history, and treatment outcomes of patients with
DHF, and few randomized controlled trials have evalu-
ted patients with HF in this setting. The Acute Decom-
ensated Heart Failure National Registry (ADHERE) was
eveloped to address this knowledge deficit (9).
The ADHERE is a large, multicenter registry designed
o prospectively collect data on episodes of ADHF hospi-
alization beginning with the point of initial care in the
ospital or emergency department and ending with the
atient’s discharge, transfer out of the hospital, or in-
ospital death. Registry-participating sites include more
han 275 community, tertiary, and academic medical centers
rom all regions of the U.S. and are representative of the
ation’s hospitals as a whole. The registry provides a unique
pportunity to evaluate how patients admitted with HF are
anaged under “real-world” treatment conditions.
On the basis of previous observations (10–12), we pos-
ulated that the choice of intravenous (IV) vasoactive
herapy might influence inpatient outcome in patients with
DHF. Specifically, we hypothesized that in ADHERE,
V natriuretic peptides and/or IV vasodilators would be
ssociated with lower rates of in-hospital mortality than
ould IV positive inotropic agents when patients were
valuated using proper adjustment for baseline differences
redicting both treatment selection (using propensity score)
nd the risk of in-hospital mortality (using multivariable
egression analysis). This analysis was undertaken in the first
5,180 patient cases entered into the ADHERE registry
hrough July 2003.
ETHODS
he primary objectives of the ADHERE registry are to
escribe the demographic and clinical characteristics of
atients hospitalized with ADHF, characterize the initial
mergency department evaluation and subsequent inpatient
anagement, and identify trends and changes in medical
anagement over time (9). In addition, the registry was
esigned to track adherence to quality measures and to assist
ospitals in evaluating and improving quality of care for
atients hospitalized with ADHF. A Scientific Advisory
ommittee participated in the design of ADHERE (Ap-
endix). This committee oversees the ongoing conduct of
Abbreviations and Acronyms
ADHERE  Acute Decompensated Heart Failure
National Registry
ADHF  acute decompensated heart failure
BUN  blood urea nitrogen
CI  confidence interval
HF  heart failure
IV  intravenous
LVEF  left ventricular ejection fraction
OR  odds ratiohe registry and has full access to the registry data. aatients and data collection. Consecutive patients who
re admitted to a participating acute care hospital and given
discharge diagnosis of HF are eligible for entry into the
egistry. Patients are excluded if HF is not the principal
ocus of diagnosis or treatment during the admission or if
heir medical record cannot be accessed for administrative
easons. Otherwise, and in contrast to a clinical trial, there
re no inclusion or exclusion criteria for enrollment in the
DHERE. Patient demographics, medical history, clinical
resentation, laboratory results, treatment course, and clin-
cal outcomes data are collected by chart review and entered
sing a Web-based electronic data capture system via an
lectronic case report form. Patient identifiers are not used
n the collection of data. For our study, medical institution
eview board approval for data collection was obtained at
articipating centers, as required.
ortality analysis. The present analysis was designed to com-
are the effects of four different IV vasoactive medications—
itroglycerin, nesiritide, milrinone, and dobutamine—on the rates
f in-hospital mortality in patients with ADHF. The effects of
itroprusside could not be assessed because there were
nadequate patient numbers, i.e., 1% of the total study
opulation (92% of whom also received concomitant ne-
iritide, nitroglycerin, dobutamine, or milrinone), for mean-
ngful statistical analysis. In contrast to randomized con-
rolled trials, all therapeutic regimens captured in the
DHERE database are based on clinician judgment and
ot on a study protocol. Such imbalances may not only
nfluence treatment selection, but they may predict outcome
in this case, in-hospital mortality). Thus, imbalances be-
ween groups require adjustment for baseline differences to
rovide valid between-group comparisons. Before and after
uch adjustments, the following pair-wise comparisons were
onducted on ADHERE registrants: nitroglycerin versus
ilrinone, nitroglycerin versus dobutamine, nesiritide ver-
us milrinone, nesiritide versus dobutamine, nesiritide ver-
us nitroglycerin, and dobutamine versus milrinone.
The comparison of in-hospital mortality between pairs of
reatments involved several steps. First, the important pre-
ictors of mortality were identified based on all patients
nrolled in ADHERE using classification and regression
ree analysis (CART, version 5.0, Salford Systems, San Diego,
alifornia) of 38 variables describing patients’ baseline charac-
eristics and clinical presentation (Table 1). CART is an
mpiric, statistical method based on recursive partitioning
nalyses (13). It segregates the different values of a classifi-
ation variable through a binary decision tree composed of a
rogression of binary splits on the values of the predictor
ariables. Patients with missing predictor variables were
ncluded in the analysis using “surrogate” variables contain-
ng information similar to that contained in the primary
plitters. The tree was constrained to have a minimum node
ize of 1,000 patient cases in the parent nodes and a
inimum final node size of 500 patient cases. In addition,
10-fold cross-validation was used to assess the predictivebility of the tree model. The final tree model was con-
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July 5, 2005:57–64 Hospital Mortality in Decompensated HFrmed by logistic regression with the criterion of p  0.001
or inclusion in the model. Continuous predictors were
ichotomized based on cutoff points suggested by the tree
nalysis, and the odds ratios (ORs) for death were calcu-
ated, along with corresponding 95% confidence intervals
CIs), for each predictor.
Second, to adjust for differences in baseline clinical and
emographic characteristics between patient treatment
roups, a propensity score analysis was conducted for each
air-wise comparison using CART models (14–16). The
ropensity score is the conditional probability of assignment
able 1. Variables Tested for Their Predictive Potential for
n-Hospital Mortality
Demographic characteristics
Age
Height
Race
Gender
Baseline clinical characteristics
BNP concentration
BUN concentration
Congestion on first chest X-ray
Creatinine concentration
DBP
Duration of symptoms before hospitalization
Elevated cardiac enzymes (troponin I positive or 1 ng/ml;
troponin T positive or 0.1 ng/ml; CK-MB 5% of total CK)
Heart rate
Hemoglobin concentration
LVEF (40% or moderately/severely impaired ejection fraction at
presentation or prehospitalization
NYHA functional classification at presentation or pre-hospitalization
Presence of dyspnea at rest
Presence of fatigue
Presence of peripheral edema
Presence of rales
QRS duration 120 ms
Sodium concentration
SBP
Weight
Coexisting conditions
History of atrial fibrillation
History of COPD/asthma
History of chronic renal insufficiency
History of CAD
History of diabetes
History of hyperlipidemia/dyslipidemia
History of hypertension
History of ischemic heart disease
History of heart failure
History of myocardial infarction
History of revascularization
History of PVD
History of stroke
History of ventricular tachycardia or fibrillation
Other
Insurance type (Medicare/Medicaid vs. other)
NP  B-type natriuretic peptide; BUN  blood urea nitrogen; CAD  coronary
rtery disease; CK-MB  creatinine kinase-MB fraction; COPD  chronic obstruc-
ive pulmonary disease; DBP  diastolic blood pressure; LVEF  left ventricular
jection fraction; NYHANew York Heart Association; PVD peripheral vascular
isease; SBP  systolic blood pressure.o a particular treatment given observed covariates; this tcore has been shown to produce unbiased estimates of the
reatment effect in observational studies. Patients taking
oth medications were excluded from each pair-wise com-
arison. The trees were constrained to have a minimum
ode size of 900 patient cases in the parent nodes and a
inimum final node size of 300 patient cases.
The final step in the analysis was logistic regression to
ompare the mortality of patients treated with different
edications, adjusting for mortality risk factors, treatment
ropensity score, and gender. The use of mortality risk
actors as dichotomous variables with cutoff points identi-
ed by tree analysis led to equivalent results; therefore,
ortality risk factors (except for dyspnea) and propensity
core were included as continuous variables in the final
ogistic regression model to fully use the information avail-
ble in these variables. The Hosmer-Lemeshow test was
sed to assess goodness of fit. The area under the receiver
perator curve was used to assess model discrimination. Un-
djusted ORs, ORs adjusted for risk factors, and ORs adjusted
or risk factors and propensity score, along with their corre-
ponding 95% CIs and p values, were reported. Because of
ultiple pair-wise comparisons, only p values 0.008 were
onsidered significant using strict Bonferroni correction. All
nalyses were performed using SAS version 8.0 (SAS
nstitute, Cary, North Carolina), unless noted otherwise.
ESULTS
atient demographics and drug administration. Between
ctober 2001 and July 2003, a total of 65,180 patient cases
rom 263 hospitals were enrolled in the ADHERE. On
verage, patients were 72.5  13.9 years of age. Fifty-two
ercent were women. Fifty-eight percent had coronary
rtery disease; a history of hypertension (72%), diabetes
ellitus (44%), atrial fibrillation (30%), and renal insuffi-
iency (29%) were common types of comorbidity. During
ospitalization, 15,230 (23.4%) of these cases received IV
asoactive treatment consisting of nitroglycerin (n 6,549),
esiritide (n  5,220), milrinone (n  2,021), or dobut-
mine (n  4,226). The mean maximal dose during the
nitial 24 h of the infusion was 24.9 g/min for nitroglyc-
rin, 0.02 g/kg/min for nesiritide, 0.54 g/kg/min for
ilrinone, and 6.05 g/kg/min for dobutamine. Sixteen
ercent of patient cases received more than one of these
edications, with 14.2% of patient cases receiving two study
edications, 1.9% receiving three study medications, and
.1% receiving all four study medications. Demographic and
linical characteristics of registry patients by treatment are
isted in Table 2.
In general, patients treated with IV vasoactive agents
ere more likely than other registry participants to be
ounger and male and to have ischemic HF, coronary artery
isease, renal insufficiency, serum creatinine concentrations
f 2 mg/dl, and lower left ventricular ejection fractions
LVEFs). Patients treated with dobutamine or milrinone
ended to have higher blood urea nitrogen (BUN) levels,
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Hospital Mortality in Decompensated HF July 5, 2005:57–64able 2. Demographic Characteristics, Baseline Clinical Characteristics, and Outcome Measures for ADHERE Patients
Parameter
Nitroglycerin*
(n  6,549)
Nesiritide*
(n  5,220)
Milrinone*
(n  2,021)
Dobutamine*
(n  4,226)
All Other Patients†
(n  49,950)
emographics
Age (yrs)
Mean  SD 71.2  13.4 70.9  13.6 67.3  14.0 70.4  13.5 73.1  14.0
Median (Q1, Q3)‡ 73.4 (62.7, 81.1) 73.3 (62.8, 81.0) 69.7 (58.4, 77.6) 73.0 (62.8, 80.2) 75.8 (64.5, 83.3)
Gender
Female, n (%) 3,467 (53) 2,215 (42) 668 (33) 1,559 (37) 26,948 (54)
edical history
Ischemic heart failure etiology,
n/total (%)
1,203/2,259 (53) 1,588/2,769 (57) 778/1,253 (62) 1,440/2,416 (60) 8,125/17,615 (46)
CAD, n/total (%) 4,163/6,548 (64) 3,599/5,220 (69) 1,345/2,021 (67) 2,952/4,226 (70) 27,613/49,948 (55)
Renal insufficiency, n/total (%) 2,061/6,549 (31) 2,025/5,220 (39) 807/2,021 (40) 1,759/4,226 (42) 13,579/49,949 (27)
Atrial fibrillation, n/total (%) 1,491/6,549 (23) 1,782/5,220 (34) 662/2,021 (33) 1,434/4,226 (34) 15,327/49,949 (31)
Diabetes, n/total (%) 3,175/6,549 (48) 2,592/5,220 (50) 879/2,021 (43) 1,909/4,226 (45) 21,561/49,950 (43)
Hypertension, n/total (%) 5,247/6,549 (80) 3,695/5,220 (71) 1,182/2,021 (58) 2,633/4,226 (62) 36,010/49,950 (72)
Hyperlipidemia, n/total (%) 2,644/6,549 (40) 2,043/5,220 (39) 758/2,021 (38) 1,609/4,226 (38) 16,350/49,949 (33)
PVD, n (%) 1,266/6,549 (19) 1,088/5,220 (21) 366/2,021 (18) 811/4,226 (19) 8,406/49,950 (17)
COPD/asthma, n (%) 1,962/6,549 (30) 1,615/5,220 (31) 537/2,021 (27) 1,286/4,226 (30) 15,520/49,949 (31)
aseline oral neurohormonal medications
Beta-blocker, n/total (%) 3,369/6,543 (52) 2,804/5,219 (54) 1,125/2,020 (56) 2,001/4,224 (47) 22,277/49,912 (45)
ACE inhibitor, n/total (%) 2,757/6,543 (42) 2,282/5,219 (44) 933/2,020 (46) 1,856/4,224 (44) 20,160/49,912 (40)
ARB, n/total (%) 773/6,543 (12) 644/5,219 (12) 260/2,020 (13) 524/4,224 (12) 5,591/49,912 (11)
Spironolactone, n/total (%) 480/6,543 (7) 870/5,219 (17) 492/2,020 (24) 800/4,224 (19) 4,280/49,912 (9)
nitial evaluation
BUN (mg/dl)
Mean  SD 30.3  19.2 37.5  23.6 41.9  26.5 42.5  27.1 30.6  20.2
Median (Q1, Q3) 24.0 (17.0, 38.0) 31.0 (20.0, 49.0) 35.0 (23.0, 55.0) 35.0 (22.4, 56.0) 25.0 (17.0, 38.0)
Creatinine (mg/dl)
Mean  SD 1.9  1.9 1.7  1.0 1.8  1.1 1.9  1.2 1.7  1.7
Median (Q1, Q3) 1.3 (1.0, 1.9) 1.5 (1.1, 2.1) 1.6 (1.2, 2.1) 1.6 (1.2, 2.3) 1.3 (1.0, 1.8)
Creatinine 2 mg/dl, n/total (%) 1,450/6,454 (22) 1,319/5,119 (26) 541/1,939 (28) 1,341/4,124 (33) 9,035/49,084 (18)
Sodium (mmol/l)
Mean  SD 138.7  4.4 137.6  4.9 136.5  5.3 136.5  5.3 138.3  4.9
Median (Q1, Q3) 139.0 (136.0, 142.0) 138.0 (135.0, 141.0) 137.0 (134.0, 140.0) 137.0 (134.0, 140.0) 139.0 (136.0, 141.0)
Hemoglobin (g/dl)
Mean  SD 12.7  2.7 12.3  2.4 12.6  2.5 12.6  2.8 12.4  2.7
Median (Q1, Q3) 12.5 (11.0, 14.0) 12.1 (10.7, 13.7) 12.2 (10.9, 13.8) 12.3 (10.8, 13.9) 12.2 (10.8, 13.7)
SBP (mm Hg)
Mean  SD 163.0  37.1 137.4  32.2 121.3  27.4 124.0  29.3 144.6  31.0
Median (Q1, Q3) 160.0 (135.5, 191.0) 133.0 (113.0, 156.0) 117.0 (101.0, 138.0) 120.0 (102.0, 141.0) 142.0 (122.0, 164.0)
SBP 90 mm Hg, n/total (%) 60/6,420 (1) 155/5,192 (3) 160/2,002 (8) 347/4,196 (8) 886/49,636 (2)
DBP (mm Hg)
Mean  SD 88.8  25.3 76.4  19.8 70.1  17.6 70.1  18.2 77.4  19.1
Median (Q1, Q3) 86.0 (70.0, 105.0) 74.0 (62.0, 88.0) 69.0 (59.0, 80.0) 69.0 (58.0, 80.0) 76.0 (64.0, 89.0)
Heart rate (beats/min)
Mean  SD 95.9  24.0 88.3  21.7 87.3  21.0 87.3  21.2 88.0  21.6
Median (Q1, Q3) 94.0 (78.0, 112.0) 85.0 (72.0, 102.0) 84.0 (72.0, 100.0) 84.0 (72.0, 100.0) 85.0 (72.0, 100.0)
QRS 120 ms, n/total (%) 1,804/5,980 (30) 2,013/4,533 (44) 834/1,607 (52) 1,753/3,573 (49) 13,470/43,305 (31)
LVEF 40% or moderate-to-severe
impairment, n/total (%)
3,000/5,565 (54) 3,219/4,539 (71) 1,639/1,847 (89) 3,099/3,715 (83) 19,221/38,961 (49)
Dyspnea at rest, n/total (%) 3,115/6,549 (48) 2,150/5,220 (41) 665/2,021 (33) 1,701/4,226 (40) 16,554/49,950 (33)
Peripheral edema, n/total (%) 3,979/6,549 (61) 3,846/5,220 (74) 1,328/2,021 (66) 2,898/4,226 (69) 33,164/49,950 (66)
Fatigue, n/total (%) 1,735/6,549 (26) 1,954/5,220 (37) 902/2,021 (45) 1,818/4,226 (43) 16,280/49,950 (33)
Rales, n/total (%) 5,028/6,549 (77) 3,653/5,220 (70) 1,269/2,021 (63) 2,862/4,226 (68) 33,546/49,950 (67)
ime to therapy (h)
Mean  SD 15.9  52.8 30.2  64.0 54.3  106.0 48.6  82.0 NA
Median (Q1, Q3) 1.3 (0.5, 5.1) 7.8 (3.3, 28.1) 18.4 (4.6, 67.7) 17.6 (4.0, 62.5) NA
utcome measures
ICU length of stay (d)
Mean  SD 3.9  5.2 4.6  5.8 6.9  8.3 6.1  7.4 3.2  4.0
Median (Q1, Q3) 2.4 (1.4, 4.3) 3.2 (2.0, 5.4) 4.3 (2.4, 8.0) 4.0 (2.1, 7.1) 2.0 (1.0, 3.9)
Total length of stay (d)
Mean  SD 7.1  7.1 7.9  7.1 10.9  10.0 10.0  9.0 5.3  4.5
Median (Q1, Q3) 5.1 (3.2, 8.4) 6.0 (3.8, 9.9) 8.0 (4.7, 13.9) 7.7 (4.7, 12.6) 4.1 (2.7, 6.6)
Mortality, n/total (%) 310/6,549 (4.7) 370/5,220 (7.1) 248/2,021 (12.3) 589/4,226 (13.9) 1,563/49,950 (3.1)
Patients receiving more than one therapy are counted in multiple treatment groups. †Patients not receiving nesiritide, nitroglycerin, dobutamine, or milrinone. ‡25th percentile
Q1) and 75th percentile (Q3).
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; ICU  intensive care unit; other abbreviations as in Table 1.
l
L
n
n
n
p
a
t
t
a
w
t
e
I
a
c
l
P
o
c
m
h
v
t
r
p
n
s
f
p
w
t
e
i
w
m
(
2
l
1
b
a
a
c
O
e
d
u
t
rate; O
61JACC Vol. 46, No. 1, 2005 Abraham et al.
July 5, 2005:57–64 Hospital Mortality in Decompensated HFower blood pressure, greater QRS duration, and lower
VEF than patients who were treated with nesiritide or
itroglycerin. Relative to nitroglycerin, patients treated with
esiritide tended to have higher BUN levels, serum creati-
ine concentrations of  2 mg/dl, lower systolic blood
ressure and diastolic blood pressure, greater QRS duration,
nd lower LVEF. Nearly one-half (46%) of all nitroglycerin-
reated patients had preserved left ventricular systolic func-
ion (LVEF40%). Females represented a smaller percent-
ge of patients treated with inotropes than patients treated
ith vasodilators. Nitroglycerin therapy was provided earlier
han nesiritide, which in turn was administered earlier than
ither inotrope.
n-hospital outcome. The mean length of hospital stay
nd mean length of stay in the intensive care unit/coronary
are unit for patients receiving IV vasoactive agents were
onger than those for other registry patients (Table 2).
atients treated with nitroglycerin or nesiritide had shorter
verall lengths of stay in the hospital and in the intensive
are unit/coronary care units than patients treated with
ilrinone or dobutamine. Furthermore, unadjusted in-
ospital mortality was lower among patients treated with a
asodilator or natriuretic peptide compared with patients
reated with an inotrope (4.7% and 7.1% for patients
eceiving nitroglycerin and nesiritide, respectively, com-
Table 3. Mortality Predictors Selected by Clas
Parameter
Died
(n  2675)
Age (yrs)
Mean  SD 77.4  12.2
Median (Q1, Q3)* 79.6 (71.3, 86.0
Age 78 vs. 78
BUN (mg/dl)
Mean  SD 47.9  29.7
Median (Q1, Q3) 40.0 (26.0, 61.0
BUN 42 vs. 42
Serum Cr (mg/dl)
Mean  SD 2.1  1.7
Median (Q1, Q3) 1.7 (1.2, 2.5)
Cr 3.2 vs. 3.2
SBP (mm Hg)
Mean  SD 124.9  29.9
Median (Q1, Q3) 122 (104, 143)
SBP 115 vs. 115
DBP (mm Hg)
Mean  SD 67.7  18.5
Median (Q1, Q3) 67 (55, 78)
DBP 55 vs. 55
Serum sodium (mmol/l)
Mean  SD 136.5  6.2
Median (Q1, Q3) 137 (133, 140)
Sodium 134 vs. 134
HR (beats/min)
Mean  SD 90.7  23.3
Median (Q1, Q3) 88 (74, 105)
HR 84 vs. 84
Dyspnea at rest, n (%) 1,220 (46%)
*25th percentile (Q1) and 75th percentile (Q3).
CI  confidence interval; Cr  creatinine; HR  heartared with 12.3% and 13.9% for patients receiving milri- mone and dobutamine, respectively). Because there were
ubstantial differences in baseline characteristics and risk
actors between these treatment groups, adjustments for
ropensity of receiving a particular IV vasoactive treatment
ere performed to compare mortality rates.
Of the 65,180 patients analyzed in the ADHERE regis-
ry, 2,675 (4.1%) died while hospitalized. Table 3 shows the
ight parameters that were predictive of in-hospital mortal-
ty based on the CART model. Risk of in-hospital mortality
as significantly increased in patients with BUN levels 42
g/dl (OR  3.34), systolic blood pressure 115 mm Hg
OR  3.09), diastolic blood pressure 55 mm Hg (OR 
.87), serum sodium 134 mmol/l (OR  2.26), creatinine
evels 3.2 mg/dl (OR  1.99), age 78 years (OR 
.88), dyspnea at rest (OR  1.57), and heart rate 84
eats/min (OR  1.20).
The unadjusted ORs for in-hospital mortality, ORs
djusted for the eight covariates and gender, and ORs
djusted for the covariates and propensity score and their
orresponding CIs and p values are shown in Table 4.
verall, survival was better in patients receiving nitroglyc-
rin or nesiritide than in patients receiving milrinone or
obutamine for both unadjusted and adjusted ORs. The
nadjusted odds of mortality were higher with nesiritide
han with nitroglycerin, but once proper adjustments were
tion Tree Model
Survived
(n  62,505)
OR of Death
(95% CI)
72.3  14.0
74.9 (63.7, 82.5)
1.88 (1.74–2.04)
31.2  20.5
25.0 (17.0, 39.0)
3.34 (3.08–3.62)
1.7  1.7
1.3 (1.0, 1.8)
1.99 (1.78–2.24)
145.0  32.4
142 (121, 165)
3.09 (2.85–3.35)
78.3  20.1
76 (64, 90)
2.87 (2.62–3.14)
138.2  4.8
139 (136, 141)
2.26 (2.08–2.47)
88.5  21.8
86 (73, 101)
1.20 (1.11–1.30)
21,757 (35%) 1.57 (1.45–1.70)
R  odds ratio; other abbreviations as in Table 1.sifica
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Hospital Mortality in Decompensated HF July 5, 2005:57–64imilar effects on mortality. Patients receiving nesiritide had
covariate- and propensity score-adjusted OR for mortality
f 0.94 (95% CI 0.77 to 1.16, p  0.58) compared with
atients receiving nitroglycerin. The unadjusted OR was
igher for dobutamine than for milrinone and remained
igher once adjusted for covariates and propensity score.
atients receiving dobutamine had a covariate- and propen-
ity score-adjusted OR of 1.24 (95% CI 1.03 to 1.55, p 
.027) compared with patients receiving milrinone. Of the
atients who received vasoactive agents, 579 (3.8%) had a
ystolic blood pressure 90 mm Hg. Exclusion of these
atients from the analyses did not significantly alter the
djusted mortality ORs between treatment groups.
ISCUSSION
he present study demonstrates significant differences in out-
ome, particularly for in-hospital mortality, based on the choice
f IV vasoactive medication used in the treatment of ADHF.
pecifically, the present analysis contributes to our fund of
nowledge by showing that mortality is similar with the
atriuretic peptide nesiritide and the vasodilator nitroglycerin
ut significantly higher with the use of the positive inotropic
gents dobutamine and milrinone. This observation may have
ignificant implications for IV drug selection in the manage-
ent of such patients, suggesting that natriuretic peptides and
asodilators should be preferred over positive inotropic agents
n patients with ADHF requiring treatment with an IV
asoactive drug. Each of these IV vasoactive agents is com-
only used to treat ADHF patients, and each has a unique
echanism of action and risk/benefit profile (17–19).
Dobutamine is a direct-acting positive inotropic agent
ith primary activity resulting from the stimulation of
eta-adrenergic receptors in the heart (17). Milrinone, a
yclic adenosine monophosphate-specific phosphodiesterase
nhibitor, produces positive inotropic and vasodilatory ef-
ects independent of beta-adrenergic receptor stimulation
ut acts in the heart via the same signal-transduction
athway as dobutamine (18,19). Nitroglycerin reduces pre-
oad and afterload by dilating peripheral capacitance and
able 4. Mortality Odds Ratios in Pair-Wise Treatment Compar
Analysis*
NTG (n  6,055)
vs.
MIL (n  1,660)
NTG (n  5,713)
vs.
DOB (n  3,478)
NES
MIL
nadjusted 0.34 (0.28–0.41)† 0.24 (0.20–0.28)† 0.53
djusted for covariates 0.69 (0.54–0.88)† 0.46 (0.38–0.57)† 0.59
djusted for covariates
and propensity score¶
0.69 (0.53–0.89)† 0.46 (0.37–0.57)† 0.59
osmer-Lemeshow goodness-of-fit test not significant at 5% levels for the models
omparison, where p 0.04. Area under the receiver operator curve 0.70 or higher.
sing Bonferroni correction. *Patients taking both medications were excluded from eac
or covariate and propensity score adjustment. Covariates include age, gender, SBP
ropensity score by treatment comparison are: NES vs. DOB: SBP, sodium, BUN,
TG vs. DOB: SBP, sodium, BUN, heart rate, LVEF, symptom duration; NTG
evascularization; NES vs. NTG: SBP, BUN, creatinine, LVEF, symptom duration
yspnea, VTF.
DOB  dobutamine; HF  heart failure; LVEF  left ventricular ejection fract
ventricular tachycardia/fibrillation; other abbreviations as in Table 1.esistance vessels through a direct interaction with receptors Tn vascular smooth muscle cells. Nesiritide is the first drug
f its class, the natriuretic peptides, to be used clinically in
he management of ADHF. It provides benefit in patients
ith ADHF via a combination of neurohormonal as well as
emodynamic and renal effects (20–24).
Given these various mechanisms of action, it is not
urprising that dobutamine is associated with an increase in
yocardial oxygen consumption, heart rate, and risk of
rrhythmias (25,26), whereas milrinone produces tachycar-
ia and other arrhythmias and is limited by hypotension in
any patients (10,26). Thus, the clinical “cost” of positive
notropic therapy may manifest as life-threatening adverse
vents in patients with ADHF. In addition, stimulation of
he beta-adrenergic signal-transduction pathway has been
mplicated in HF disease progression, providing the rationale
or beta-adrenergic receptor blockade in the treatment of
hronic HF (27). The present analysis from the ADHERE
uggests that such stimulation, when delivered exogenously,
lso may exert a deleterious effect on the natural history of
DHF. These findings are supported by other observations,
ncluding those from randomized controlled trials demon-
trating worse outcomes with positive inotropic agents
ompared with placebo (i.e., standard care) (10,28,29).
asodilators and natriuretic peptides lower ventricular fill-
ng pressures and systemic vascular resistance and improve
ardiac performance indirectly via these unloading effects
24,30). They do not stimulate tachycardia or other arrhyth-
ias but do exhibit the risk of hypotension (25,31). How-
ver, in controlled studies, the risk of symptomatic hypo-
ension is low (4% to 5%) with either nesiritide or the
itrovasodilators (11). Despite this risk of hypotension, the
ifferentiated safety concerns in the present analysis from
he ADHERE favors the use of nesiritide or vasodilators
ver positive inotropic agents in the treatment of ADHF.
Because nitroglycerin and nesiritide appear to be equally
afe in the treatment of ADHF, other effects must be
onsidered when choosing between these agents. At the
resent time, nitroglycerin has been studied more exten-
ively and used in patients with acute ischemic syndromes.
4,663)
.
1,534)
NES (n  4,270)
vs.
DOB (n  3,301)
NES (n  4,402)
vs.
NTG (n  5,668)
DOB (n  3,656)
vs.
MIL (n  1,496)
–0.64)† 0.37 (0.32–0.44)† 1.64 (1.38–1.94)† 1.39 (1.15–1.68)†
–0.73)† 0.47 (0.39–0.56)† 0.95 (0.78–1.16)‡ 1.27 (1.04–1.56)§
–0.73)† 0.47 (0.39–0.56)† 0.94 (0.77–1.16)‡ 1.24 (1.03–1.55)§
ed for risk factors and/or propensity, except for covariate-adjusted NTG vs. DOB
e of multiple pair-wise comparisons, only p values0.008 were considered significant
-wise analysis. †p 0.005. ‡p 0.58. §p 0.021 for covariate adjustment and 0.027
P, BUN, creatinine, sodium, heart rate, and dyspnea. ¶Covariates included in the
ine, age, weight, LVEF, edema; NES vs. MIL: SBP, age, LVEF, dyspnea, weight;
MIL: SBP, BUN, LVEF, symptom duration, dyspnea, QRS 120 ms, previous
a, previous HF, QRS 120 ms; DOB vs. MIL: SBP, age, hemoglobin, heart rate,
IL  milrinone; NES  nesiritide; NTG  nitroglycerin; OR  odds ratio; VTFisons
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July 5, 2005:57–64 Hospital Mortality in Decompensated HFng or accompanying ADHF may represent a scenario in
hich nitroglycerin would be preferred. However, natri-
retic peptides also demonstrate coronary vasodilating ef-
ects, and one study of nesiritide included a small number of
atients with HF in the setting of an acute coronary
yndrome (11). Future studies may better define the role of
esiritide in such patients. Moreover, in patients with HF,
itroglycerin is associated with activation of the renin-
ngiotensin system and fluid retention (32), whereas nesirit-
de suppresses vasoconstrictive and anti-natriuretic hor-
ones (23,24). Nesiritide also exhibits favorable renal
ffects in patients with ADHF (21,33). Thus, patients with
uid retention and/or renal insufficiency may be better
andidates for treatment with nesiritide.
In a randomized controlled trial of acute decompensation
f chronic heart failure, nesiritide provided significant he-
odynamic and clinical benefits. The Vasodilation in the
anagement of Acute Congestive Heart Failure (VMAC)
rial was a randomized, double-blind, placebo-controlled
omparison of nesiritide and nitroglycerin (in addition to
tandard therapy) in patients with ADHF (11). Reductions
n pulmonary capillary wedge pressure were significantly
reater with nesiritide than with nitroglycerin, starting with
he first measurement at 15 min and persisting throughout
he first day, with no evidence of attenuation of effect
11,30). In addition, when compared with placebo, nesirit-
de, but not nitroglycerin, significantly lowered systemic
ascular resistance and increased cardiac index at 1 h and
ignificantly reduced dyspnea within 3 h after initiation of
herapy (11). Finally, nesiritide produced a trend toward
mprovement in global clinical status at 24 h relative to
itroglycerin (11).
The present analysis of the ADHERE database is limited
y a number of factors. First, the data are observational and
he analysis is retrospective. Second, clinician judgment
ather than a study protocol guided the selection of IV
asoactive medication used in a particular patient. However,
o control for such judgment, propensity scores were devel-
ped to eliminate the effects of selection bias inherent in
onrandomized trials (34). A propensity score is a scalar
ummary of an individual’s covariate information that is
qual to that individual’s conditional probability of treat-
ent, given these covariates (14,34,35). Consequently, pro-
ensity scores are balancing scores that reduce treatment
ias (14). The observed differences in this study between
nadjusted and adjusted mortality ORs (particularly in
erms of nesiritide vs. nitroglycerin) underscore the need to
erform covariate and risk adjustments. In nonrandomized
rials, balancing cohorts on the basis of propensity scores
ields the same statistical effect, with respect to the included
ovariates, as randomization does in controlled clinical
rials. Recent cardiovascular trials have used propensity
core analyses to permit a more rigorous adjustment for
election bias and confounding than is possible with stan-
ard analyses (36,37). In addition, a strength of this registry
s that it eliminates the selection bias inherent in random- dzed controlled trials. For example, randomized controlled
rials of HF generally enroll men, age 60 to 65 years, with
eft ventricular systolic dysfunction and low rates of comor-
idity. In the ADHERE registry, the average age is approx-
mately 73 years, and 52% of registrants are women.
reserved systolic function is common, and comorbidities
lso are much more prevalent. Thus, ADHERE provides
nsights into the effect of ADHF therapies in a more
epresentative ADHF population than that which is gener-
lly enrolled in randomized clinical trials.
A third limitation is that differences in clinical character-
stics between subjects who did and did not receive IV
asoactive therapy prohibited inclusion of a non-IV vasoac-
ive control group. Furthermore, because the ADHERE
egistry collects data only during the period of hospitaliza-
ion, the long-term effects of the various IV vasoactive
herapies cannot be determined. However, with respect to
hese last limitations, a recent analysis of data from the
valuation Study of Congestive Heart Failure and Pulmo-
ary Artery Catheterization Effectiveness (ESCAPE) trial
ound that patients with ADHF treated with IV vasodila-
ors had a six-month mortality risk that is similar to that of
atients with ADHF who do not require IV vasoactive
edication. In contrast, patients with ADHF treated with
n IV inotropic agent had a 1.8-fold increase in their
ix-month mortality risk (38).
In the current analysis, baseline data on cardiac and renal
unction, including blood pressure, LVEF, QRS duration,
nd BUN and serum creatinine levels, demonstrated that
atients treated with nesiritide, dobutamine, and milrinone
ended to be sicker and thus be at greater risk of dying, than
hose treated with nitroglycerin. Thus, it is not surprising
hat the unadjusted OR for mortality is higher with these
gents than with nitroglycerin in this study. Two different
ell-established statistical techniques, CART analysis and
ropensity scores, were used to adjust for these baseline
ifferences. Application of these techniques eliminated the
pparent mortality difference between nesiritide and nitro-
lycerin but not the significant mortality differences be-
ween nesiritide or nitroglycerin and dobutamine or milri-
one. Nonetheless, these statistical techniques are not
erfect and may have failed to completely control for baseline
ifferences between treatment groups, a limitation of this as
ell as all other uncontrolled retrospective analyses.
In summary, the ADHERE registry is the largest data-
ase available to characterize patients hospitalized with
DHF. Data collected from real-world analyses such as this
ne provide valuable information on treatment safety and
fficacy that is not available from highly controlled, short-
erm, clinical trials of carefully selected patient populations.
n the current analysis of data culled from the ADHERE,
ates of in-hospital mortality in patients treated with ne-
iritide were similar to those in patients treated with
itroglycerin, and nesiritide or nitroglycerin were associated
ith a significant survival benefit compared with either
obutamine or milrinone. These mortality data support the
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ropic agents in the management of patients with ADHF
ho require IV vasoactive therapy. Positive inotropic agents
hould be considered only in patients who are refractory to
reatment with vasodilators or nesiritide or in patients in
mpending cardiogenic shock.
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